TERUMO CorporationBusiness Strategy Conference                 THERAPEUTIC SYSTEMS                   & CELL PROCESSING    ...
Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field ...
Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field ...
Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field ...
Industry Examples: Cell TherapyThere are approximately 275 therapeutic companies withroughly 240 cell-based therapies that...
Cell Therapy: Cancer Vaccine                  F.D.A. Approves ‘Vaccine’ to Fight Prostate Cancer | Published: April 29, 20...
Potential Application of Cell Therapy: Mesenchymal Stem Cells                                                  MSC’s have ...
Very strong growth in MSC activityNumber of MSC                                 Number of MSC                            N...
Opportunity for Terumo BCT: Enabling Technologies           Aging Population = Clinical Opportunities                  Can...
CaridianBCT + Terumo Transfusion Facts     acquisition close:   13 April, 2011             company:     Terumo Corporation...
Value Creation: CaridianBCT + Terumo TransfusionImproving our abilities to meet the needs of blood banks, hospitals andbio...
Terumo BCT in field of Cell Therapy       We are the only company leveraging unique technology,     innovation and core co...
Overview of Customer SegmentsBLOOD CENTERS                                                        CELL COLLECTIONSHOSPITAL...
Products in the Cell Processing Value Chain   Activity:     Cells are        Cells are      Cell population       Cells ar...
Cell Therapy Product Portfolio                Quantum Cell Expansion System                                               ...
Quantum System: Benefits & Value• All required components integrated into one system   • Bioreactor, incubator, media and ...
IR Contact      TERUMO Corporation      Corporate Communication (IR) Dept.      E-mail: kouhou_terumo01@terumo.co.jp Among...
Upcoming SlideShare
Loading in...5
×

08 31-12 terumo rd-q1_3

539

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
539
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

08 31-12 terumo rd-q1_3

  1. 1. TERUMO CorporationBusiness Strategy Conference THERAPEUTIC SYSTEMS & CELL PROCESSING MARK FLOWER | GLOBAL MARKETING December 5, 2011
  2. 2. Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field in health care that translates fundamental knowledge in biology, chemistry and physics into materials,  devices, systems and therapeutic strategies, including cell‐based therapies, which  augment, repair, replace or regenerate organs and tissues. 2011/12/5 ©Terumo Corporation 2/17
  3. 3. Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field in health care that translates fundamental knowledge in biology, chemistry and physics into materials,  devices, systems and therapeutic strategies, including cell‐based therapies, which  augment, repair, replace or regenerate organs and tissues. CELL THERAPY Using cells therapeutically to repair  function to bodily tissue or organs. The  two dominant forms of cell therapy are  autologous (using one’s own cells) and  allogeneic (donated cells). 2011/12/5 ©Terumo Corporation 3/17
  4. 4. Regenerative Medicine, Cell Therapy, & Cell ProcessingRegenerative Medicine is a rapidly evolving interdisciplinary field in health care that translates fundamental knowledge in biology, chemistry and physics into materials,  devices, systems and therapeutic strategies, including cell‐based therapies, which  augment, repair, replace or regenerate organs and tissues. CELL THERAPY CELL PROCESSING Using cells therapeutically to repair  function to bodily tissue or organs. The  A comprehensive term that applies to the steps  two dominant forms of cell therapy are  involved in the manufacturing of a cellular therapy  product.  For our purposes, cell processing  autologous (using one’s own cells) and  encompasses but is not limited to: allogeneic (donated cells). • CELL WASHING • VOLUME REDUCTION • CELL SEPERATION • MEDIA EXCHANGE • CELL CONCENTRATION • CELL HARVEST • CELL EXPANSION/CULTURE 2011/12/5 ©Terumo Corporation 4/17
  5. 5. Industry Examples: Cell TherapyThere are approximately 275 therapeutic companies withroughly 240 cell-based therapies that are currently on the market or in some stage of clinical development.* Tigenix: Chondrocelect - (approved in EU) expanded autologous cartilage used to repair cartilage defects Advanced BioHealing - Dermagraft: - human fibroblast derived dermal substitute Dendreon: Provenge - the first (FDA approved) therapeutic  cellular immunotherapy to treat prostate cancer*Buckler, Lee. Cell Therapy Industry Overview: Products and Applications, CELL MANUFACTURING 2010SYMPOSIUM, October 13, 2010. 2011/12/5 ©Terumo Corporation 5/17
  6. 6. Cell Therapy: Cancer Vaccine F.D.A. Approves ‘Vaccine’ to Fight Prostate Cancer | Published: April 29, 2010Terumo BCT is the global leader in therapeutic apheresisand cell collection. Terumo BCT technology is used. 2011/12/5 ©Terumo Corporation 6/17
  7. 7. Potential Application of Cell Therapy: Mesenchymal Stem Cells MSC’s have many potential applications in regenerative medicine 2011/12/5 ©Terumo Corporation 7/17
  8. 8. Very strong growth in MSC activityNumber of MSC Number of MSC Number of registered Grants1 Publications1 MSC trials2 Activities projected to accelerate in 2011, making MSCs the fastest growing area of stem cell research11) Source: Mesenchymal Stem Cells, Advances and Applications , BioInformant 2010. 2011 numbers are forecasts2) Registered trials including the word “Mesenchymal”, www.clinicaltrials.gov, early 2009, early 2010, late 2010 2011/12/5 ©Terumo Corporation 8/17
  9. 9. Opportunity for Terumo BCT: Enabling Technologies Aging Population = Clinical Opportunities Cancer, Cardiac, CommercialResearch Neurological, Diabetes, etc availability The essential requirements for success of any cell therapy is: Most innovative and safety “Cell Processing Technology” Collection, washing, separation, & processing of targeted cells Controlled, efficient, cell expansionThe role played by Terumo BCT as global No.1 leader inautomated collection and therapeutic apheresis is very important. 2011/12/5 ©Terumo Corporation 9/17
  10. 10. CaridianBCT + Terumo Transfusion Facts acquisition close: 13 April, 2011 company: Terumo Corporation division: Blood Management Business chairman: David Perezcombined organization: Terumo BCT revenues: In excess of $830M in 2010 president & CEO: David Perez classification: Medical device manufacturer industry: Blood banking, transfusion medicine, cell therapies customer segments: Blood banks/centers, hospitals and biotechnology global headquarters: U.S., Lakewood, Coloradoregional headquarters: Brussels, Buenos Aires, Hong Kong, Tokyo 2011/12/5 ©Terumo Corporation 10/17
  11. 11. Value Creation: CaridianBCT + Terumo TransfusionImproving our abilities to meet the needs of blood banks, hospitals andbiotechnology customers with a wider range of solutions within: Automated Collections Therapeutic Apheresis Manual Whole Blood Processing Cell Processing Automated Whole Blood Processing Cell Collections Pathogen Reduction Technologies Cell ExpansionDelivering unsurpassed value, knowledge and quality in all aspects of ourproducts and servicesCollaborating more closely with customers to drive future innovations tomeet their needs and aspirations while continuously increasing theirefficiencyDriving the industry standards for quality, safety, service and the deliveryof innovative solutions 2011/12/5 ©Terumo Corporation 11/17
  12. 12. Terumo BCT in field of Cell Therapy We are the only company leveraging unique technology, innovation and core competencies in therapeutic apheresis, cell collections, cell processing and cell expansion. ApheresisTHERAPEUTIC APHERESIS Therapeutic Apheresis CELL PROCESSING Improving patients lives with a Providing devices that wash, separate,powerful and diverse platform to process and expand cells for research, treat multiple disease states industry and clinical use Spectra Optia ® COBE ® Spectra COBE ® 2991 Elutra ® Quantum System Apheresis System Apheresis System Cell Processor System 2011/12/5 ©Terumo Corporation 12/17
  13. 13. Overview of Customer SegmentsBLOOD CENTERS CELL COLLECTIONSHOSPITALS AND THERAPEUTIC APHERESIS CENTERS THERAPEUTIC APHERESIS CELL PROCESSINGBIOTECH AND CELL PROCESSING 2011/12/5 ©Terumo Corporation 13/17
  14. 14. Products in the Cell Processing Value Chain Activity: Cells are Cells are Cell population Cells are Cells are Cell population Cells are stored collected from separated and is analyzed and expanded washed or is analyzed and prior to patient bone marrow, sorted characterized (cultured) concentrated characterized administration cord blood, and/or modified prior to storage tissue or or administration peripheral bloodProducts:COBE Spectra COBE 2991 cell Quantum COBE 2991 cell TSCD II processor system processorSpectra Optia (Cell expansion) Elutra system Elutra system (Elutriation) TSCD II (Elutriation) TSCD II 2011/12/5 ©Terumo Corporation 14/17
  15. 15. Cell Therapy Product Portfolio Quantum Cell Expansion System Quantum SystemSpectra Optia ® Apheresis COBE ® Spectra Apheresis COBE ® 2991 System Cell Processor Elutra ® System System 2011/12/5 ©Terumo Corporation 15/17
  16. 16. Quantum System: Benefits & Value• All required components integrated into one system • Bioreactor, incubator, media and waste management• Closed system (reduced risk of contamination)• Automation and ease of use• Decreased manual labor• Controllable, reproducible processes• Process control• Scalable cell manufacturing process• Potential for improved efficiency and cost savings 2011/12/5 ©Terumo Corporation 16/17
  17. 17. IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: kouhou_terumo01@terumo.co.jp Among the information that Terumo discloses, forecasts of financial performance onfuture projections contain potential risks and uncertainty since these are forecasts onprojections made by Terumo based on limited information available at the moment ofdisclosure. Accordingly, it should be noted that actual results may differ from thoseforecasts on projections due to various factors. Factors affecting to actual resultsinclude, but are not limited to, changes in economic conditions surrounding Terumo,fluctuations of foreign exchange rates, and state of competition. The market share information in this presentation is partly derived from our ownindependent research. 2011/12/5 ©Terumo Corporation 17/17
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×